Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

ProHance Articles

Bracco and Health Trust in contrast media deal

15 October 2007

FDA call for warning on contrast agents

4 June 2007

Bracco and AmeriNet expand deal on contrast agents

24 February 2003

Eisai And B-MS To Copromote ProHance

17 July 1995

PROHANCE IN JAPAN

28 February 1994

JAPAN NEWS IN BRIEF

10 January 1994

PENDING APPLICATIONS IN US CONTINUE TO DWINDLE

19 July 1993

SIGNIFICANT MOVES BY PHARMA COS IN FT 500

1 March 1993

PROHANCE LAUNCH

22 February 1993

FDA APPROVES 26 NEWDRUGS IN 1992

25 January 1993

HAFSLUND NYCOMED DOWNGRADED

7 December 1992

CONTRAST MEDIA MARKET SLOWDOWN EXPLAINED

7 December 1992

B-MS' PROHANCE APPROVED IN USA

7 December 1992

STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB

20 April 1992

Showing 1-14 of 14 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS